Methods for measuring proteasome activity: Current limitations and future developments


Autoria(s): Liggett, Andrea; Crawford, Lisa; Walker, Brian; Morris, Treen; Irvine, Alexandra
Data(s)

01/11/2010

Resumo

The proteasome has been validated as a therapeutic target, with proteasome inhibitors showing particular efficacy in the treatment of Multiple Myeloma. A wide range of methods have been developed to profile proteasome activity. These include the current method of choice fluorogenic peptide substrates, as well as bioluminescent imaging, immunological methods, and more recently, site-specific fluorescent probes. The aim of this review is to evaluate the currently available methods for profiling proteasome activity and their suitability for use in translational studies. Ongoing development of techniques for profiling proteasome activity will facilitate future research into proteasome-related pathologies, thus accelerating the development of more specific drug regimes. (C) 2010 Elsevier Ltd. All rights reserved.

Identificador

http://pure.qub.ac.uk/portal/en/publications/methods-for-measuring-proteasome-activity-current-limitations-and-future-developments(be1e5f0c-bcdf-42d4-b330-cee3179d0f01).html

http://dx.doi.org/10.1016/j.leukres.2010.07.003

Idioma(s)

eng

Direitos

info:eu-repo/semantics/restrictedAccess

Fonte

Liggett , A , Crawford , L , Walker , B , Morris , T & Irvine , A 2010 , ' Methods for measuring proteasome activity: Current limitations and future developments ' Leukemia Research , vol 34 , no. 11 , pp. 1403-1409 . DOI: 10.1016/j.leukres.2010.07.003

Palavras-Chave #/dk/atira/pure/subjectarea/asjc/1300/1306 #Cancer Research #/dk/atira/pure/subjectarea/asjc/2700/2720 #Hematology #/dk/atira/pure/subjectarea/asjc/2700/2730 #Oncology
Tipo

article